Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

KITTEE TRC20 Token Ad

Why Adaptimmune Therapeutics Stock Is Popping Today


home / news releases / Why Adaptimmune Therapeutics Stock Is Popping Today

  • June, 27 2022 03:27 PM
  • |
  • Motley Fool
  • |
    • ADAP
    • ADAP Quote
    • ADAP Short
    • ADAP News
    • ADAP Articles
    • ADAP Message Board

Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. Specifically, the biotech's stock is currently up by a respectable 7.72% as of 2:05 p.m. ET Monday.

To put this move into the proper context, the bellwether biotech indices -- the iShares Biotechnology ETF and the SPDR S&P Biotech ETF -- are both essentially flat for the day at the time of this writing.

Image Source: Getty Images.

Continue reading

For further details see:

Why Adaptimmune Therapeutics Stock Is Popping Today

Get Email and Text Alerts for (NASDAQ:ADAP)

Get Email and Text Alerts for (NASDAQ:ADAP)

News, Short Squeeze, Breakout and More Instantly...

Tags
  • Asset Management
  • Healthcare
Share This Post

Market Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Contact the Author

Stock Information

Adaptimmune Therapeutics plc Company Name:

ADAP Stock Symbol:

NASDAQ Market:

MENU
ADAP ADAP Quote ADAP Short ADAP News ADAP Articles ADAP Message Board
Get ADAP Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

Connect Twitter with Market Wire News
RECENT ADAP NEWS
  • ADAP - Adaptimmune Reports Second-Quarter Financial Results and Business Update

    - Reaffirming financial guidance; Company funded into early 2024 - - ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress - - Quarterly call to be held toda...

  • ADAP - Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022

    Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before th...

  • ADAP - Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

    There are some incredible deals in biotech right now. Three Fool.com contributors think Adaptimmune Therapeutics (NASDAQ: ADAP) , G1 Therapeutics (NASDAQ: GTHX) , and Axsome Therapeutics (NASDAQ: AXSM) are on the verge of a big move over the next couple of years. ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2022 Market Wire News